AIがせん妄の予測精度を向上、入院患者の転帰改善へ(AI Model Improves Delirium Prediction, Leading to Better Health Outcomes for Hospitalized Patients)

ad

2025-05-07 マウントサイナイ医療システム (MSHS)

AIがせん妄の予測精度を向上、入院患者の転帰改善へ(AI Model Improves Delirium Prediction, Leading to Better Health Outcomes for Hospitalized Patients)
Comparison of monthly delirium detection rates before any ML-model deployment (pre-ML) and following deployment of the multimodal ML-delirium risk stratification model in live clinical practice (post-ML).

マウントサイナイ医科大学の研究チームは、入院患者のせん妄(急性混乱状態)を予測・管理するためのAIモデルを開発し、臨床現場での有効性を実証しました。このモデルは、電子カルテの構造化データと医療スタッフの記録を組み合わせて解析し、せん妄のリスクが高い患者を特定します。その結果、せん妄の検出率が従来の4.4%から17.2%へと約4倍に向上し、早期介入が可能となりました。また、高齢患者への不適切な薬剤使用が減少し、全体的なケアの質が向上しました。この研究は、AIを臨床ワークフローに統合することで、患者の安全性と治療成果を改善できることを示しています。

<関連情報>

せん妄リスク層別化のための機械学習マルチモーダルモデル Machine Learning Multimodal Model for Delirium Risk Stratification

Joseph I. Friedman, MD; Prathamesh Parchure, MSC; Fu-Yuan Cheng, MS; et al
JAMA Network Open  Published:May 7, 2025
DOI:10.1001/jamanetworkopen.2025.8874

Key Points

Question Can a machine learning model be used to accurately stratify risk of hospital delirium in live clinical practice?

Findings This quality improvement study including 32 284 inpatient admissions developed an automated multimodal machine learning delirium risk stratification model that demonstrated acceptable discriminative performance in live clinical practice. Additional analyses using 7023 admissions assessed for delirium with the Confusion Assessment Method showed that model deployment was associated with a significant 4-fold increase in delirium detection rates and significant reductions in daily doses of benzodiazepine and antipsychotic medications.

Meaning These findings suggest that a machine learning model may be used to automate delirium risk stratification in live clinical practice and may enhance delirium identification and care.

Abstract

Importance Automating the identification of risk for developing hospital delirium with models that use machine learning (ML) could facilitate more rapid prevention, identification, and treatment of delirium. However, there are very few reports on the performance of ML models for delirium risk stratification in live clinical practice.

Objective To report on development, operationalization, and validation of a multimodal ML model for delirium risk stratification in live clinical practice and its associations with workflow and clinical outcomes.

Design, Setting, and Participants This quality improvement study developed an ML model supported by automated electronic medical records to stratify the risk of non–intensive care unit delirium in live clinical practice using the Confusion Assessment Method as the diagnostic reference standard, with an iterative model update method. Data from patients aged at least 60 years admitted to non–intensive care units at Mount Sinai Hospital between January 2016 and January 2020 were used to train and test the ML model presented. The model was validated in live clinical practice from March 2023 to March 2024. Analysis of the model’s associations with workflow and clinical outcomes was conducted retrospectively in 2024, comparing hospitalized patients prior to deployment of any model version (pre-ML cohort) and during model clinical deployment (post-ML cohort).

Main Outcomes and Measures Outcomes of interest were area under the receiver operating characteristic curve, monthly delirium detection rates, median length of hospital stay, and daily doses of opiate, benzodiazepine, and antipsychotic medications administered.

Results The overall sample included 32 284 inpatient admissions (mean [SD] age, 73.56 (9.67) years, 15 157 [46.9%] women). A total of 25 261 inpatient admissions of older patients with both medical and surgical primary diagnoses represented the combined model testing and training cohort (median age, 73.37 [66.42-81.36] years) and live clinical deployment validation cohort (median [IQR] age, 72.11 [62.26-78.97] years), while 7023 inpatient admissions of older patients with both medical and surgical primary diagnoses represented the combined pre-ML (median [IQR] age, 74.00 [68.00-81.00] years) and post-ML (median [IQR] age, 75.33 [68.34-82.91] years) cohorts. The model presented is a fusion of electronic medical record patient data features and clinical note features processed by natural language processing. The results of model validation in live clinical practice included an area under the curve of 0.94 (95% CI, 0.93-0.95). Median (IQR) monthly delirium detection rates of inpatients assessed for delirium with the Confusion Assessment Method increased from 4.42% (95% CI, 3.70%-5.14%) in the pre-ML cohort to 17.17% (95% CI, 15.54%-18.80%) in the post-ML cohort (P < .001). Post-ML vs pre-ML cohorts received lower daily doses of benzodiazepines (median [IQR] 0.93 [0.42-2.28] diazepam dose equivalents vs 1.60 [0.66-4.27] diazepam dose equivalents; P < .001) and olanzapine (median [IQR], 1.09 [0.38-2.46] mg vs 2.50 [1.17-6.65] mg; P < .001).

Conclusions and Relevance This quality improvement study demonstrates the feasibility of a novel multimodal ML model to automate delirium risk stratification in live clinical practice. The model demonstrated acceptable performance in live clinical practice and may facilitate resource allocation to enhance delirium identification and care.

医療・健康
ad
ad
Follow
ad
タイトルとURLをコピーしました